Fig 1: Hypoxia-dependent overexpression of MAP17 in HCC. a Venn diagram showed differentially expressed genes (DEGs) related to hypoxia and glycolysis in HCC; The Cancer Genome Atlas (TCGA) cohort (n = 369) was used for identifying glycolysis-related genes and hypoxia-related genes in HCC. b Immunohistochemical analysis of MAP17 protein expression in 202 matched HCC tissues and nontumor tissues; representative images of MAP17 staining were shown at the left panel; right panel showed the number of specimens displaying high or low MAP17 staining within the tumor or nontumor tissues (Fisher’s exact test, ***P < 0.001); scale bar: 50 μm. c Kaplan-Meier curve analysis for overall survival was performed according to MAP17 expression in HCC patients (n = 202); HR: hazard ratio. d Real-time qPCR and western blotting analysis of MAP17 expression in liver cancer cell lines. e-f SK-H929, MHCC-97H, and Huh7 cells were cultured under hypoxia (1% O2) and normoxia (20% O2) for 24 h, followed by detection of MAP17 mRNA expression by real-time qPCR (e, n = 3) and western blotting (f), respectively. g-h Under hypoxic culture condition (1% O2), MAP17 expression in MHCC-97H and Huh7 cells in the presence or absence of HIF1α knockdown was analyzed by real-time qPCR (G, n = 3) and western blotting (h), respectively. i Chromatin immunoprecipitation-PCR validation of the regulatory role of HIF-1α in MAP17 expression. Input and ChIP cycle threshold (Ct) values were normalized separately to control as 1. *P < 0.05; **P < 0.01; ***P < 0.001
Fig 2: The effect of MAP17 on the growth and proliferation of HCC cells in vitro(A, B) The silent effect of siRNA was assessed by qRT-PCR in SMMC7721 (A) and Huh7 (B). (C, D) The cell growth curves after downregulation of MAP17 were determined by the CCK-8 assay in SMMC7721 (C) and Huh7 (D). SiRNA-NC was used as control. (E, F) Clone formation assay was performed in SMMC7721 (E) and Huh7 cells (F), with siRNA-NC serving as a control. Histograms represent the mean numbers of colonies obtaining from triplicate tests (mean±SD). (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
Fig 3: Knockdown of MAP17 inhibited the invasion and migration of HCC cells in vitro(A, B) Silencing of MAP17 significantly decreased the invasion ability of SMMC7721 (A) and Huh7 (B) cells compared with control group. (C, D) Transwell migration assay illustrated that knockdown of MAP17 significantly reduced the migration of SMMC7721 (C) and Huh7 (D) compared with control group. The histograms represent the mean values of invasive and migrated cells per field (from at least 5 fields, mean ± SD) (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
Fig 4: MAP17 correlates p-AKT and HIF1α in clinical HCC samples. a Correlation between MAP17 expression and HIF1α or p-AKT level in human HCC tissues (n = 202). b Gene set enrichment analysis of gene sets related to MAP17 expression in TCGA HCC cohort; NES, normalized enrichment score; false discovery rate (FDR) was set at 0.25. c Schematic diagram for MAP/ROS-mediated metabolic modes and tumor growth in HCC
Fig 5: AKT and HIF1α are the downstream effectors of ROS in HCC. a RNA sequencing analysis of the transcriptional changes induced by MAP17 knockdown in HCC-LM3 cells; ClueGO analysis of the differentially expressed genes by CytoScape software. b The effect of MAP17 knockdown on the activity of ROS-associated signaling pathways (p38 MAPK, ERK1/2, AKT, STAT3, P70S6K, and HIF1α) in SMCC-7721 and HCC-LM3 cells was analyzed by western blotting. c The effect of MAP17 or MAP17-PDZm overexpression on AKT activity in the presence or absence of 10 mM N-acetyl cysteine (NAC) treatment was determined by western blotting. d Western blotting analysis of MAP17 or MAP17-PDZm overexpression on HIF1α protein in the presence or absence of 10 mM N-acetyl cysteine (NAC) treatment. e The effect of MAP17 or MAP17-PDZm overexpression on HIF1α transcriptional activity in MHCC-97H cells. f Western blotting analysis of HIF1α protein level in MAP17-overexprssing or vector control cells at indicated times upon 20 μg/ml CHX treatment. g Western blotting analysis of HIF1α protein level in MAP17 knockdown or overexpression cells treated with 10 μM MG132 under hypoxic conditions. *P < 0.05 and **P < 0.01
Supplier Page from Abcam for Anti-Map17 antibody [EPR10372]